or Try an Advanced Search...

    Technical Analysis for HOOK - HOOKIPA Pharma Inc.

    Grade Last Price % Change Price Change
    F 2.48 -8.90% -0.24
    HOOK closed down 2.51 percent on Wednesday, November 20, 2024, on 1.36 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical HOOK trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish -8.90%
    NR7 Range Contraction -8.90%
    Lower Bollinger Band Walk Weakness -8.90%
    New 52 Week Low Weakness -8.90%
    Wide Bands Range Expansion -8.90%
    Below Lower BB Weakness -8.90%
    Down 3 Days in a Row Weakness -8.90%
    Down 4 Days in a Row Weakness -8.90%
    Down 5 Days in a Row Weakness -8.90%
    Lower Bollinger Band Touch Weakness -8.90%
    Older End-of-Day Signals for HOOK ...

       Recent Intraday Alerts

    Alert Time
    3x Volume Pace about 1 hour ago
    Down 10% about 1 hour ago
    Down 1 ATR about 2 hours ago
    60 Minute Opening Range Breakdown about 3 hours ago
    Down 5% about 3 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    HOOK Chart by TradingView
    Basic chart:

    Profile

    HOOKIPA Pharma Inc. Description

    HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Infectious Diseases Hepatitis B Transplantation Immunodeficiency Hepatitis B Virus Viral Disease Papillomavirus Gilead Sciences Immunotherapeutics Kidney Transplant

    Is HOOK a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 17 Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky
    Nov 17 HOOKIPA Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
    Nov 15 HOOKIPA Pharma GAAP EPS of -$1.10, revenue of $4.7M
    Nov 14 HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates
    Nov 11 HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker
    Oct 31 HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
    Oct 30 HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
    Sep 24 HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
    Sep 2 Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet
    Aug 30 HOOKIPA Pharma Announces Board of Directors Changes
    See more HOOK news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 11.3
    52 Week Low 2.62
    Average Volume 41,700
    200-Day Moving Average 6.16
    50-Day Moving Average 3.95
    20-Day Moving Average 3.54
    10-Day Moving Average 3.26
    Average True Range 0.26
    RSI (14) 20.00
    ADX 27.57
    +DI 8.75
    -DI 32.36
    Chandelier Exit (Long, 3 ATRs) 3.36
    Chandelier Exit (Short, 3 ATRs) 3.39
    Upper Bollinger Bands 4.33
    Lower Bollinger Band 2.75
    Percent B (%b) -0.02
    BandWidth 44.68
    MACD Line -0.32
    MACD Signal Line -0.23
    MACD Histogram -0.0892
    Fundamentals Value
    Market Cap 262.62 Million
    Num Shares 96.6 Million
    EPS -0.80
    Price-to-Earnings (P/E) Ratio -3.40
    Price-to-Sales 3.25
    Price-to-Book 0.70
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.01
    Resistance 3 (R3) 3.00 2.91 2.96
    Resistance 2 (R2) 2.91 2.83 2.91 2.94
    Resistance 1 (R1) 2.81 2.79 2.77 2.82 2.93
    Pivot Point 2.72 2.72 2.69 2.72 2.72
    Support 1 (S1) 2.62 2.64 2.58 2.63 2.51
    Support 2 (S2) 2.53 2.60 2.53 2.50
    Support 3 (S3) 2.43 2.53 2.48
    Support 4 (S4) 2.44